



MEDICARE FORM

Evenity® (romosozumab-aqqg) Injectable Medication Precertification Request

Page 1 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
For other lines of business:
Please use commercial form.

Note: Evenity is non-preferred.
The preferred products are
Prolia and IV zoledronic acid.

Would you like to use electronic prior authorization? Consider using **Availity**, our electronic prior authorization portal. Learn more about **Availity** from the links in the table below.

For phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.

For **Aetna Medicare Advantage** and **Allina Health Aetna Medicare** members send request to:

Phone: [1-866-503-0857](tel:1-866-503-0857) (TTY: [711](tel:1-866-503-0857))

Fax: [1-844-268-7263](tel:1-844-268-7263)

Availity: <https://www.aetna.com/health-care-professionals/resource-center/availability.html>

For Aetna Medicare Advantage **Virginia Dual Eligible Special Needs Plans** (HMO D-SNP) send request to:

Phone: [1-855-463-0933](tel:1-855-463-0933)

Fax: [1-833-280-5224](tel:1-833-280-5224)

Availity: <https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal>

For Aetna Assure Premier Plus Medicare Advantage **New Jersey Dual Eligible Special Needs Plans** (HMO D-SNP) send request to:

Phone: [1-844-362-0934](tel:1-844-362-0934)

Fax: [1-833-322-0034](tel:1-833-322-0034)

Availity: <https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html>

For Aetna Better Health of **Illinois Premier Medicare Medicaid Plan** (MMP) send request to:

Phone: [1-866-600-2139](tel:1-866-600-2139)

FAX: [1-855-320-8445](tel:1-855-320-8445)

Availity: <https://www.aetnabetterhealth.com/illinois/providers/portal>

For Aetna Better Health of **Ohio Premier Medicare Medicaid Plan** (MMP) send request to:

Phone: [1-855-364-0974](tel:1-855-364-0974)

Fax: [1-855-734-9389](tel:1-855-734-9389)

Availity: <https://www.aetnabetterhealth.com/ohio/providers/portal>

For Aetna Better Health of **Michigan Premier Medicare Medicaid Plan** (MMP) send request to:

Phone: [1-855-676-5772](tel:1-855-676-5772)

Fax: [1-844-241-2495](tel:1-844-241-2495)

Availity: <https://www.aetnabetterhealth.com/michigan/providers/portal.html>



MEDICARE FORM

Evenity® (romosozumab-aqqg) Injectable Medication Precertification Request

Page 2 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Evenity is non-preferred. The preferred products are Prolia and IV zoledronic acid.

Please indicate: [] Start of treatment: Start date ___/___/___ [] Continuation of therapy: Date of last treatment ___/___/___

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

Form section A: Patient Information. Fields include First Name, Last Name, Address, City, State, ZIP, Home Phone, Work Phone, Cell Phone, DOB, Allergies, E-mail, Current Weight, Height.

B. INSURANCE INFORMATION

Form section B: Insurance Information. Fields include Aetna Member ID #, Group #, Insured, Does patient have other coverage?, Carrier Name, Insured.

C. PRESCRIBER INFORMATION

Form section C: Prescriber Information. Fields include First Name, Last Name, Address, City, State, ZIP, Phone, Fax, St Lic #, NPI #, DEA #, UPIN, Provider Email, Office Contact Name, Phone.

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Form section D: Dispensing Provider/Administration Information. Divided into Place of Administration and Dispensing Provider/Pharmacy. Includes checkboxes for Self-administered, Physician's Office, Outpatient Infusion Center, Home Infusion Center, Administration code(s) (CPT).

E. PRODUCT INFORMATION

Form section E: Product Information. Request is for: Evenity® (romosozumab-aqqg): Dose: _____ Frequency: _____ HCPCS Code: _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Form section F: Diagnosis Information. Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

Form section G: Clinical Information. For Initiation Requests (clinical documentation required for all requests): Note: Evenity is non-preferred. The preferred products are Prolia and IV zoledronic acid. Includes questions about prior therapy and adverse reactions.

Continued on next page



MEDICARE FORM

Evenity® (romosozumab-aqqg) Injectable Medication Precertification Request

Page 3 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
For other lines of business:
Please use commercial form.

Note: Evenity is non-preferred.
The preferred products are Prolia
and IV zoledronic acid.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) - Required clinical information must be completed in its entirety for all precertification requests.

Please provide the patient's Bone Mineral Density (BMD) score and date obtained: T-score: _____ Date: ____/____/____

Please indicate the location the BMD was measured: femoral neck lumbar spine total hip other: please identify: _____

Yes No Is the patient receiving 1000mg of calcium and 400 international units of vitamin D daily?

Yes No Does the patient have clinical evidence of uncorrected preexisting hypocalcemia?

Yes No Is the patient at high risk for fractures?

Yes No Has the patient had an osteoporotic fracture?

→ Yes No Does the patient have multiple risk factors for fractures?

Please explain (select all that apply): alcohol intake of 4 or more units per day parental history of hip fracture

rheumatoid arthritis current tobacco smoking none of the above

For All Requests:

Post-menopausal osteoporosis

Yes No Is there documentation that the trial of 2 oral and/or injectable bisphosphonates was ineffective?

→ Yes No Is there documentation that a trial of 1 bisphosphonate AND 1 selective estrogen receptor modulator (SERM) was ineffective?

→ Please identify the failure of the medication trial: Continued bone loss Other: please identify: _____

Bisphosphonate #1 Date range: ____/____/____ - ____/____/____

Bisphosphonate #2 OR SERM Date range: ____/____/____ - ____/____/____

Yes No Is there documented evidence that the patient has an intolerance to bisphosphonates and/or SERMs?

→ Select all that apply: bisphosphonates SERM

Yes No Is there documented evidence that the patient has a contraindication to bisphosphonates and/or SERMs?

→ Select all that apply: bisphosphonates SERM

Please select which of the following bisphosphonates and/or SERM's was ineffective, not tolerated or contraindicated:

Select all that apply: Alendronate (Binosto, Fosamax or Fosamax plus D) Etidronate disodium (Didronel) Ibandronate (Boniva)

Risedronate (Actonel, Actonel with Calcium or Atelvia) Tiludronate (Skelid) Zoledronic acid (Zometa, Reclast)

Raloxifene (Evista) Tamoxifen (Nolvadex/Soltamox) Toremifene citrate (Fareston) Other: Please identify: _____

For Continuation Requests: (Clinical documentation required for all requests)

Yes No Does the patient have a hypersensitivity to romosozumab-aqqg?

Please indicate what type of response the patient has experienced while on romosozumab-aqqg: No response Minimal response

Adequate response Significant improvement

Please indicate How many monthly doses of Evenity has the patient received: 12 monthly doses or greater Less than 12 monthly doses

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ Date: ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.